What Are the Differences Between GLP-1 and GLP-2?

GLP-1 and GLP-2 are sibling hormones cut from the same precursor protein, but they do fundamentally different jobs in the body. GLP-1 is best known for controlling blood sugar and suppressing appetite, which is why drugs that mimic it (semaglutide, liraglutide) have become blockbuster treatments for diabetes and obesity. GLP-2, by contrast, is a gut-repair specialist: it promotes the growth and health of the intestinal lining and has been developed into a therapy for people who have lost so much bowel that they cannot absorb enough nutrition to survive. Despite sharing roughly 70% of their amino acid sequence, these two peptides activate separate receptors in different tissues and produce strikingly different downstream effects.

A Shared Origin, Then a Fork in the Road

Both GLP-1 and GLP-2 start life as part of a single large protein called proglucagon. In the pancreas, proglucagon is chopped up to produce glucagon, the hormone that raises blood sugar. But in the intestine, a different set of molecular scissors processes the same proglucagon into GLP-1, GLP-2, and a few other peptide fragments.¹ Both hormones are released from L-cells, specialized nutrient-sensing cells concentrated in the lower small intestine and colon, and both enter the bloodstream together after a meal.

Their amino acid sequences overlap substantially. The two peptides share about 70% sequence similarity, with nearly identical residues at their tips (the first six amino acids and the last fifteen or so). Where they diverge is in the middle stretch of the chain, which is the region responsible for docking into each peptide’s specific receptor.² That central region is why GLP-1 binds the GLP-1 receptor and GLP-2 binds the GLP-2 receptor, with very little cross-talk between the two systems.

Where Their Receptors Show Up Determines What They Do

The most consequential difference between GLP-1 and GLP-2 is where each one’s receptor is found. The GLP-1 receptor is widely distributed: pancreatic beta cells, the brain, the heart’s sinoatrial node, kidney and lung arteries, and more.³ That widespread footprint explains why GLP-1 has such varied effects: stimulating insulin release, slowing stomach emptying, reducing appetite, and influencing heart rate.

The GLP-2 receptor, by comparison, is expressed almost exclusively in the stomach and bowel.⁴ Within the gut, it sits not on the absorptive cells lining the intestinal wall but on enteric neurons and certain enteroendocrine cells.⁵ Some of those neurons produce nitric oxide and vasoactive intestinal peptide, signaling molecules that help control local blood flow.⁶ So GLP-2 works through the gut’s own nervous system rather than acting directly on the cells it ultimately nourishes. Think of it as giving orders through a chain of command inside the intestinal wall rather than walking up and doing the job itself.

GLP-1 Controls Blood Sugar and Appetite

GLP-1’s headline function is the incretin effect. When you eat, the spike in GLP-1 tells pancreatic beta cells to release more insulin, but only when blood glucose is actually elevated. This glucose-dependent mechanism is what makes GLP-1-based drugs relatively safe from causing dangerously low blood sugar.⁷ At the same time, GLP-1 tells the pancreas to dial back glucagon, the hormone that would otherwise push blood sugar higher.

Beyond the pancreas, GLP-1 slows how fast food leaves the stomach and acts on brain circuits to reduce hunger. Research has shown that GLP-1 receptor agonist-induced weight loss requires GLP-1 receptors in the central nervous system. Specific neurons in the brain’s arcuate nucleus, an area involved in energy balance, are activated by GLP-1 receptor agonists and drive weight loss.⁸ These combined gut-pancreas-brain effects are the reason GLP-1 receptor agonists have become important drugs for both type 2 diabetes and obesity. Semaglutide, for instance, was the first long-acting GLP-1 receptor agonist approved by the FDA specifically for managing obesity.⁹

GLP-2 Grows and Repairs the Gut

GLP-2’s primary job is intestinal maintenance. It stimulates cell proliferation in the gut lining, expanding the mucosal surface area that absorbs nutrients. In experimental models of intestinal disease, GLP-2 reduces damage and accelerates healing.¹⁰ The effect is not instant: in neonatal piglets, measurable increases in crypt cell proliferation and decreases in intestinal cell death became statistically clear after about 48 hours of GLP-2 infusion.¹¹

GLP-2 also boosts blood flow to the intestinal lining, which supports nutrient absorption and tissue repair. And it plays a less intuitive role in how the gut handles dietary fat. After a meal, GLP-2 promotes the release of chylomicrons, the lipid-carrying particles that shuttle dietary fats from intestinal cells into the bloodstream. Experiments in healthy volunteers showed that a dose of GLP-2 increased circulating intestinal-origin lipid particles even hours after eating, suggesting GLP-2 can mobilize previously stored fat from the gut wall.¹² Whether this lipid-mobilizing action is helpful or problematic in different clinical contexts is still being sorted out.¹³

They Share a Vulnerability but Differ in Half-Life

Both GLP-1 and GLP-2 are broken down by the same enzyme, dipeptidyl peptidase IV (DPP-IV), which snips off their first two amino acids and renders them inactive.¹⁴ That N-terminal fragment is essential for receptor binding, so once it is clipped, the hormone is essentially dead.¹⁵ This shared vulnerability is why DPP-IV inhibitors (a class of diabetes drugs) can boost the activity of both peptides at once.

Native GLP-1 is famously short-lived, with a circulating half-life of only about two minutes. Native GLP-2 lasts somewhat longer, typically around seven minutes, though in porcine infusion studies roughly a third of the infused GLP-2 was degraded to an inactive fragment during continuous delivery.¹⁶ Both half-lives are far too brief for practical drug use, which is why the pharmaceutical versions of each peptide have been engineered to resist DPP-IV cleavage and survive in the body for hours or even days.

Different Effects on Blood Flow

Even their vascular effects are tissue-specific. A systematic review of microcirculation studies found that GLP-1 appears to regulate blood flow in the pancreas, skeletal muscle, and cardiac muscle, consistent with its role in glucose handling. GLP-2, on the other hand, acts mainly on blood flow within the mid-intestine.¹⁷

A double-blinded trial in healthy volunteers tested whether GLP-1 might also increase intestinal blood flow, the way GLP-2 does. It did not. Neither GLP-1 nor its breakdown product changed blood flow in the mesenteric or renal arteries. GLP-1 did, however, increase heart rate compared to placebo and tended to raise cardiac output.¹⁸ So even where you might expect overlap, the two hormones target different vascular beds.

The Gut-Bone Axis

One area where both peptides play a role, but through different mechanisms, is bone turnover. After a meal, bone resorption (the breakdown of old bone) slows down. The gut hormones released during eating appear to contribute to this effect. Both GLP-1 and GLP-2, along with a third gut hormone called GIP, have been linked to postprandial changes in bone turnover markers.¹⁹

The way they go about it differs. GLP-1 acts directly on bone-forming cells (osteoblasts), boosting new bone formation and reducing breakdown. GLP-2 has little effect on bone formation; instead, it mainly increases bone density by slowing bone resorption.²⁰ In people with type 2 diabetes, infusing GLP-1 or GLP-2 individually during a glucose challenge each suppressed a bone resorption marker called β-CTX-I, but not by as much as a normal oral glucose load. When GIP, GLP-1, and GLP-2 were all infused together, the suppression matched what happens after swallowing glucose, suggesting these hormones work together to produce the full postprandial bone effect.²¹

Different Clinical Applications

The drug development paths for GLP-1 and GLP-2 have gone in completely different directions, reflecting their distinct biology. GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide, and others) are now among the most prescribed drugs in the world, used primarily for type 2 diabetes and obesity. The appetite-suppressing and insulin-boosting properties of GLP-1 translate into meaningful weight loss and improved blood sugar control across large clinical trials.²²

GLP-2 drug development has been far more niche. The main therapeutic use is teduglutide, a DPP-IV-resistant analog of GLP-2 that is given by daily injection to patients with short bowel syndrome and intestinal failure. These patients have had so much of their intestine surgically removed, often because of Crohn’s disease, vascular accidents, or other catastrophic bowel problems, that they cannot absorb enough fluid and nutrients from food alone and depend on intravenous nutrition. Teduglutide promotes structural repair and growth of the remaining intestine, reducing diarrhea and allowing patients to decrease their dependence on intravenous support.²³ Clinical studies have confirmed that teduglutide increases intestinal wet-weight absorption and urine output while reducing the volume of parenteral support patients require.²⁴

The patient populations could hardly be more different. GLP-1 drugs target tens of millions of people worldwide with common metabolic conditions. GLP-2 therapy serves a small population with a rare surgical complication. Yet both were born from the same precursor molecule.

Antiapoptotic Effects in Different Tissues

Both GLP-1 and GLP-2 help keep cells alive, but in their respective target organs. GLP-1 has antiapoptotic effects on pancreatic beta cells, helping to preserve the insulin-producing cell mass that erodes in type 2 diabetes. GLP-2 exerts similar cell-survival effects on the gut epithelium, protecting the intestinal lining from excessive cell death.¹⁰ The parallel is elegant: one hormone guards the organ that manages blood sugar, the other guards the organ that absorbs the nutrients creating that blood sugar in the first place.

A Drug That Activates Both Receptors

Given that GLP-1 and GLP-2 are co-secreted after every meal and clearly play complementary roles, researchers have wondered whether a single drug that activates both receptors at once might produce benefits that neither can achieve alone. Dapiglutide is an experimental dual GLP-1/GLP-2 receptor agonist designed to do exactly that. In a mouse model of short bowel with 40% intestinal resection, dapiglutide promoted intestinal growth while also reducing food intake and affecting body weight and stool water content, combining the gut-repair activity of GLP-2 with the metabolic effects of GLP-1.²⁵ Further preclinical work showed that dapiglutide also improved gut barrier function in the short bowel model.²⁶

Dapiglutide has now entered human trials. In a randomized, placebo-controlled proof-of-concept study in people with obesity, the side-effect profile was dominated by gastrointestinal complaints early in treatment: reduced appetite, nausea, diarrhea, and constipation, which were mostly mild to moderate and clustered in the first four to eight weeks. About 56% of participants receiving dapiglutide reported nausea compared with 38% on placebo, and 61% reported reduced appetite compared with 33% on placebo.²⁷ The dual-agonist concept is still early, but it reflects a broader trend in metabolic medicine toward multi-receptor drugs, and the idea that replacing what the gut naturally co-secretes might be smarter than targeting one receptor at a time.

An Evolutionary Puzzle

The evolutionary history of GLP-1 and GLP-2 adds another layer to their differences. The proglucagon gene has been remarkably stable across vertebrates, but the individual hormones it encodes have not evolved at the same rate. GLP-1 underwent a major shift in function during early vertebrate evolution: in fish, it acts more like a glucagon-like hormone, but in mammals it became an incretin, tightly coupled to meal-related insulin release.²⁸

GLP-2 took a different evolutionary path. Its amino acid sequence went through a burst of rapid change during early mammalian evolution, suggesting it acquired a new biological function that is not shared with non-mammalian vertebrates.²⁸ A more recent analysis across dozens of mammalian species found that GLP-2 sequences display more variability than GLP-1, and that the GLP-2 receptor has undergone the most rapid protein sequence evolution among all proglucagon-derived peptide receptors. Despite this faster drift, most of the amino acid changes in the GLP-2 receptor were not predicted to have functional consequences, suggesting that the receptor tolerates more variation while still doing its job.²⁹

Why GLP-2 evolved faster than GLP-1 in mammals remains an open question. One plausible idea is that the selective pressure on a hormone maintaining the gut lining shifts significantly when an animal changes its diet, digestive anatomy, or gut microbiome composition, all of which vary enormously across mammalian species. GLP-1, with its tighter link to blood-sugar regulation, may face more uniform constraints because glucose metabolism works similarly across most mammals. Whatever the reason, the evolutionary divergence mirrors the functional divergence: GLP-1 is the metabolic generalist, GLP-2 the intestinal specialist, and their separate evolutionary speeds reflect the different pressures each system faces.